THE ADENOASSOCIATED VIRUS REP78 MAJOR REGULATORY TRANSFORMATION SUPPRESSOR PROTEIN BINDS CELLULAR SP1 IN-VITRO AND EVIDENCE OF A BIOLOGICALEFFECT/

Citation
Pl. Hermonat et al., THE ADENOASSOCIATED VIRUS REP78 MAJOR REGULATORY TRANSFORMATION SUPPRESSOR PROTEIN BINDS CELLULAR SP1 IN-VITRO AND EVIDENCE OF A BIOLOGICALEFFECT/, Cancer research, 56(22), 1996, pp. 5299-5304
Citations number
44
Categorie Soggetti
Oncology
Journal title
ISSN journal
00085472
Volume
56
Issue
22
Year of publication
1996
Pages
5299 - 5304
Database
ISI
SICI code
0008-5472(1996)56:22<5299:TAVRMR>2.0.ZU;2-U
Abstract
Adeno-associated virus (AAV) Rep78 is a multifunctional protein that i s required for AAV transcriptional activity, AAV DNA replication, and possibly for site-specific integration of AAV into human chromosome 19 . Rep78 is also able to inhibit a variety of heterologous promoters, i ncluding those of c-H-ras, human papillomavirus types 16 and 18, and H IV type 1. However, Rep78 is unable to significantly affect murine ost eosarcomavirus (MSV). It was noticed that promoters that are inhibited possess binding motifs for the cellular transcription factor Sp1, whe reas the MSV long terminal repeat promoter did not. These data stimula ted the hypothesis that Rep78 may recognize and interact with cellular Sp1. Here, we demonstrate that Rep78 is able to interact with Sp1 in vitro as analyzed by West(far)-Western, electrophoretic mobility shift assay-supershift, and coimmunoprecipitation analyses. Furthermore, in support of an in vivo biological effect from this interaction, Rep78 is demonstrated to inhibit a synthetic, Sp1-dependent promoter. Furthe r still, the insertion of Sp1 DNA binding motifs into the Rep78-resist ant MSV long terminal repeat results in a promoter that has increased sensitivity to inhibition by Rep78. Finally, it is demonstrated that t he Sp1-Rep78 interaction requires the amino half of Rep78. The interac tion of Rep78 with Sp1, along with possible downstream effects on the transcription initiation process of RNA polymerase II, may partially e xplain the rather broad-based antitumor abilities of AAV.